Literature DB >> 16098229

Acute cytomegalovirus infection complicated by venous thrombosis: a case report.

Clarisse Rovery1, Brigitte Granel, Philippe Parola, Cédric Foucault, Philippe Brouqui.   

Abstract

BACKGROUND: CMV-induced vasculopathy and thrombosis have been reported, but they are rare conditions usually encountered in immunocompromised patients. However more and more complications of CMV infections are recognized in immunocompetent patients. CASE
PRESENTATION: We present a case report of a previously healthy adult with cytomegalovirus infection that was complicated by tibiopopliteal deep venous thrombosis and in whom Factor V Leiden heterozygous mutation was found.
CONCLUSION: This new case report emphasizes the involvement of cytomegalovirus in induction of vascular thrombosis in patients with predisposing risk factors for thrombosis. It is necessary to screen for CMV infection in patients with spontaneous thrombosis and an history of fever.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098229      PMCID: PMC1198216          DOI: 10.1186/1476-0711-4-11

Source DB:  PubMed          Journal:  Ann Clin Microbiol Antimicrob        ISSN: 1476-0711            Impact factor:   3.944


Backgound

CMV-induced vasculopathy and thrombosis have been reported, but they are rare conditions. The few published reports on these conditions focus either on immunocompromised transplant recipients who are receiving high-dose immunosuppressive agents [1,2] or on HIV-infected patients [3-5]. We report one new case of acute CMV infection in a non-immunocompromised adult that presented as spontaneous venous thrombosis. There are few reports involving immunocompetent adults, and these reports are additional arguments for the implication of CMV in vasculopathy and thrombosis.

Case presentation

A 33-year-old white man with a 5-day history of fever, was hospitalized on May 2004. He also reported epigastralgia and pain in the right leg. He had an history of femoral deep venous thrombosis ten years before. His mother and his brother had an history of deep venous thrombosis and his father died because of pulmonary embolism. Physical examination revealed fever (temperature range 38°C–38°5C), asthenia, headache, anorexia and epigastralgia. His right leg was enlarged and painful. Tibiopopliteal deep venous thrombosis was confirmed by Doppler ultrasonography. At the time of hospital admission, his WBC was 6,000 cells/mm3, with 2,100 neutrophils/mm3 and 2,820 lymphocytes/mm3, with 9% of hyperbasophilic lymphocytes. His platelet count was 120,000/mm3 and his hemoglobin level was 141 g/l. The C-reactive protein level was 52 mg/l. Liver function tests revealed an ALT level of 65 UI/l, an AST level of 64 UI/l, an LDH level of 891 UI/l, a PAL level of 61 UI/l and a γ-GT level of 41 UI/l. Blood cultures were sterile. The results of serological tests for HIV ELISA, hepatitis A IgM, hepatitis B surface antigen, hepatitis C virus, Q fever, and toxoplasma were negative. VCA and EBNA IgG antibodies were positive suggesting past immunization. Serological test for CMV ELISA was strongly positive for IgM antibodies. The result of a CMV pp65 antigenemia assay, based on the direct detection of the CMV pp65 phosphoprotein was positive. A second serological test for CMV taken two weeks after the first one showed seroconversion with appearance of IgG. No pathological values for prothrombin time ratio, activated partial thromboplastin time, plasma antithrombin III, protein C and S activity were found. Results of tests for anticardiolipin antibodies, lupus anticoagulant and prothrombin 20210 were negative. Antinuclear antibodies were negative and complement was normal. Factor V Leiden heterozygous mutation was found. Anticoagulant treatment was introduced. Tthe patient became asymptomatic and was discharged from the hospital.

Discussion

Our observation, as well those of others [6,7], argues for implication of CMV in vasculopathy and thrombosis. In these cases, thrombosis occurred in immunocompetent patients during CMV infection, which was confirmed, in most cases, by pp65 antigen and/or CMV viremia/viruria. There are few reports involving immunocompetent adults since we retrieved only 13 reports through MEDLINE database [6-16]. Predisposing risk factors for thrombosis have sometimes been found in the reported cases such as protein C and S deficiency [15] and the presence of antiphospholipid antibodies [10,13,16,17]. In other reports, patients were women and had risk factors such as oral contraceptive use [8,9,14]. The factor V Leiden heterozygous mutation was only reported once previously [6]. However in some other reported cases, no hemostatic abnormalities can be found [6,7,17] and spontaneous resolutions of thrombosis were observed in some of these patients who did not receive anticoagulant treatment [9]. This suggests that CMV was the sole triggering factor. These observations suggest that acute CMV infection may be the cause of the thrombosis event in these patients. However, it is difficult to determine whether CMV is a direct cause of thrombosis or a precipitating factor in patients with underlying thrombogenic tendency. Considering that CMV could be a transient triggering factor for thrombosis in our patient, we decided not to treat lifelong as recommended for patients with factor V Leiden heterozygous mutation and 2 spontaneous thrombosis [18] but only for 6 months [19]. In conclusion, our case report reinforces the opinion that CMV is a rare but potentially signifiant cause or precipitating factor of arterial and venous thrombosis in immunocompetent hosts [20]. It seems to be necessary to screen for CMV infection in patients with spontaneous thrombosis and an history of fever. It is important to recognize CMV infection in these patient as it may be possible to consider the discontinuation of anticoagulant therapy earlier.
  19 in total

1.  Cytomegalovirus infection as a cause of acute superior mesenteric vein thrombosis with jejunal infarction.

Authors:  Stéphane Benoist; Marie-jo Laisné; Francisca Joly; Mourad Boudiaf; Yves Panis; Patrice Valleur
Journal:  Surgery       Date:  2003-02       Impact factor: 3.982

2.  Cytomegalovirus infection and thrombosis: a causative association?

Authors:  P Youd; J Main; E Jackson
Journal:  J Infect       Date:  2003-02       Impact factor: 6.072

3.  Thromboembolic disease in AIDS is associated with cytomegalovirus disease.

Authors:  R E Jenkins; B S Peters; A J Pinching
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

4.  Neonatal aortic arch thrombosis as a result of congenital cytomegalovirus infection.

Authors:  M Lanari; T Lazzarotto; I Papa; V Venturi; G Bronzetti; B Guerra; G Faldella; L Corvaglia; F M Picchio; M P Landini; G P Salvioli
Journal:  Pediatrics       Date:  2001-12       Impact factor: 7.124

5.  [Spontaneous portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent patient].

Authors:  J L Estival; P Debourdeau; C Zammit; L Teixeira; S Guérard; B Colle
Journal:  Presse Med       Date:  2001-12-15       Impact factor: 1.228

Review 6.  Effects of human cytomegalovirus infection on the coagulation system.

Authors:  Alessandro Squizzato; Victor E A Gerdes; Harry R Büller
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

7.  Portal vein thrombosis caused by protein C and protein S deficiency associated with cytomegalovirus infection.

Authors:  R Arav-Boger; S Reif; Y Bujanover
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

Review 8.  Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis.

Authors:  Andrew D Auerbach; Gillian D Sanders; Julie Hambleton
Journal:  Am J Med       Date:  2004-06-15       Impact factor: 4.965

Review 9.  Vascular thrombosis and acute cytomegalovirus infection in immunocompetent patients: report of 2 cases and literature review.

Authors:  Pierre Abgueguen; Valérie Delbos; Jean Marie Chennebault; Christopher Payan; Eric Pichard
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079

10.  Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts.

Authors:  P K Koskinen; M S Nieminen; L A Krogerus; K B Lemström; S P Mattila; P J Häyry; I T Lautenschlager
Journal:  J Heart Lung Transplant       Date:  1993 Sep-Oct       Impact factor: 10.247

View more
  7 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  Antiphospholipid antibody syndrome with thrombotic splenic infarcts associated with acute cytomegalovirus infection.

Authors:  Christopher Denham; Ginger Tissier; Amit Golding
Journal:  Access Microbiol       Date:  2019-06-10

3.  Pulmonary embolism and portal vein thrombosis in an immunocompetent adolescent with acute cytomegalovirus hepatitis.

Authors:  Antonio Mendoza Ladd; Rakesh Goyal; Louis Rosainz; Peter Baiocco; Larry DiFabrizio
Journal:  J Thromb Thrombolysis       Date:  2008-12-31       Impact factor: 2.300

4.  Small-bowel necrosis complicating a cytomegalovirus-induced superior mesenteric vein thrombosis in an immunocompetent patient: a case report.

Authors:  John Kalaitzis; Paris Basioukas; Eftalia Karzi; Charalampos Markakis; Emmanouil Liarmakopoulos; Andreas Hadjimarkou; Spyros Rizos
Journal:  J Med Case Rep       Date:  2012-04-24

Review 5.  Risk factors of venous thrombo-embolism during cytomegalovirus infection in immunocompetent individuals. A systematic review.

Authors:  Manuela Ceccarelli; Emmanuele Venanzi Rullo; Giuseppe Nunnari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-18       Impact factor: 5.103

Review 6.  Venous thromboembolism related to cytomegalovirus infection: A case report and literature review.

Authors:  Amar H Kelkar; Kavitha S Jacob; Eman B Yousif; John J Farrell
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 7.  Hyperthrombotic Milieu in COVID-19 Patients.

Authors:  Mohamed Hassan Kamel; Wenqing Yin; Chris Zavaro; Jean M Francis; Vipul C Chitalia
Journal:  Cells       Date:  2020-10-31       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.